☆ 4.7 Review

Rapid Response of Refractory Systemic Lupus Erythematosus Skin Manifestations to Anifrolumab-A Case-Based Review of Clinical Trial Data Suggesting a Domain-Based Therapeutic Approach

JOURNAL OF CLINICAL MEDICINE (2022)

Related references

Note: Only part of the references are listed.

Article Rheumatology

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis

David Jayne et al.

Summary: This study evaluated the efficacy and safety of anifrolumab, a type I interferon receptor antibody, in patients with active lupus nephritis. The results showed that anifrolumab IR had numerical improvements over placebo in several endpoints, including complete renal response. However, the primary endpoint of improvement in 24-hour urine protein-creatinine ratio was not met.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Rheumatology

Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials

Eric F. Morand et al.

Summary: This post-hoc analysis aimed to evaluate the efficacy of anifrolumab on organ domain-specific SLE disease activity. The results demonstrated that anifrolumab treatment improved multiple organ systems in SLE patients, particularly the musculoskeletal system, mucocutaneous system, and immunological system.

LANCET RHEUMATOLOGY (2022)

Add to Collection

Article Rheumatology

The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease

Faye A. H. Cooles et al.

Summary: The interferon gene signature (IGS) is derived from interferon-regulated genes expression, and has been increasingly reported in rheumatic diseases as a potentially clinically relevant biomarker with multiple applications.

LANCET RHEUMATOLOGY (2022)

Add to Collection

Article Cell Biology

Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation

Allison C. Billi et al.

Summary: This study analyzed the skin and circulating immune cells of lupus patients using integrated single-cell RNA sequencing and spatial RNA sequencing. The findings reveal that the normal-appearing skin of patients with lupus is characterized by an interferon-rich environment and that CD16+ dendritic cells undergo interferon education in the skin, leading to proinflammatory phenotypes. These results provide important insights into the pathogenesis of cutaneous lupus erythematosus.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

Belimumab for systemic lupus erythematosus - Focus on lupus nephritis

Marlene Pluess et al.

Summary: Advances in the treatment and management of systemic lupus erythematosus have improved patient outcomes, but lupus nephritis remains a major complication. Belimumab has been shown to be superior as an add-on therapy for lupus nephritis, and personalized treatment options are expected with the development of new therapeutic agents.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)

Add to Collection

Review Rheumatology

Which is the best SLE activity index for clinical trials?

Koichiro Ohmura

Summary: Despite the anticipation for a paradigm shift in systemic lupus erythematosus treatment similar to that in rheumatoid arthritis, clinical trials for drugs believed to be effective have repeatedly failed. Reasons include the heterogeneity of SLE, inclusion criteria, lack of appropriate disease activity measures, and relapse criteria.

MODERN RHEUMATOLOGY (2021)

Add to Collection

Review Biotechnology & Applied Microbiology

B cell depletion therapies in autoimmune disease: advances and mechanistic insights

Dennis S. W. Lee et al.

Summary: B cells have been found to actively participate in autoimmune diseases, leading to the clinical success of B cell depletion therapies like those targeting CD20, CD19, and BAFF. Despite limited impact on antibody levels and plasma cells in controlling the disease, research on B cells is constantly evolving and developing.

NATURE REVIEWS DRUG DISCOVERY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Type I Interferons in Systemic Autoimmune Diseases: Distinguishing Between Afferent and Efferent Functions for Precision Medicine and Individualized Treatment

Francois Chasset et al.

Summary: The role of type I interferon in systemic autoimmune diseases is complex and varied, with clinical manifestations influenced by multiple factors. Studying the mechanisms and therapeutic strategies targeting high IFN-I levels is crucial for the development of precision medicine.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Rheumatology

Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study

Ian N. Bruce et al.

Summary: This multicentre, randomised, double-blind, placebo-controlled, phase 2 study aimed to evaluate the pharmacokinetics, pharmacodynamics, safety, and efficacy of subcutaneous anifrolumab in patients with SLE, active skin disease, and a high type I interferon gene signature. The results showed that subcutaneous anifrolumab had non-linear pharmacokinetics, dose-dependent neutralisation of the type I interferon gene signature, and a safety profile consistent with previous studies of intravenous anifrolumab.

LANCET RHEUMATOLOGY (2021)

Add to Collection

Editorial Material Medicine, General & Internal

A Successful Trial for Lupus - How Good Is Good Enough?

Jane E. Salmon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

Eric F. Morand et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Rheumatology

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1) a randomised, controlled, phase 3 trial

Richard A. Furie et al.

LANCET RHEUMATOLOGY (2019)

Add to Collection

Review Rheumatology

Interferon pathway in SLE: one key to unlocking the mystery of the disease

Lars Ronnblom et al.

LUPUS SCIENCE & MEDICINE (2019)

Add to Collection

Review Rheumatology

Type I interferon in rheumatic diseases

Theresa L. Wampler Muskardin et al.

NATURE REVIEWS RHEUMATOLOGY (2018)

Add to Collection

Article Cell Biology

A protective Langerhans cell-keratinocyte axis that is dysfunctional in photosensitivity

William D. Shipman et al.

SCIENCE TRANSLATIONAL MEDICINE (2018)

Add to Collection

Article Rheumatology

Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus

Jeffrey M. Riggs et al.

LUPUS SCIENCE & MEDICINE (2018)

Add to Collection

Article Rheumatology

Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

Richard Furie et al.

ARTHRITIS & RHEUMATOLOGY (2017)

Add to Collection

Article Rheumatology

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE)

Kenneth C. Kalunian et al.

ANNALS OF THE RHEUMATIC DISEASES (2016)

Add to Collection

Article Rheumatology

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

Munther Khamashta et al.

ANNALS OF THE RHEUMATIC DISEASES (2016)

Add to Collection

Review Rheumatology

New insights into the immunopathogenesis of systemic lupus erythematosus

George C. Tsokos et al.

NATURE REVIEWS RHEUMATOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Systemic lupus erythematosus

Arvind Kaul et al.

NATURE REVIEWS DISEASE PRIMERS (2016)

Add to Collection

Article Rheumatology

Dose-escalation of human anti-interferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study

Avram Goldberg et al.

ARTHRITIS RESEARCH & THERAPY (2014)

Add to Collection

Article Dermatology

The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score

I. Braunstein et al.

BRITISH JOURNAL OF DERMATOLOGY (2012)

Add to Collection

Article Dermatology

Development of the CLASI as a Tool to Measure Disease Severity and Responsiveness to Therapy in Cutaneous Lupus Erythematosus

Rachel Klein et al.

ARCHIVES OF DERMATOLOGY (2011)

Add to Collection

Review Biochemistry & Molecular Biology

Interferon Alpha as a Primary Pathogenic Factor in Human Lupus

Timothy B. Niewold

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2011)

Add to Collection

Article Biochemical Research Methods

Structural characterization of a human Fc fragment engineered for lack of effector functions

Vaheh Oganesyan et al.

ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.